The Pharm So Hard Podcast

Episode 50. The Immune System Needs to Calm Down: Pharmacologic Management with Tocilizumab and Baricitinib

Jimmy Pruitt

5 years ago

Tocilizumab and Baricitinib Mechanisms of Action

COVID-19 Pathogenesis: Late COVID-19

In the late stage, pulmonary edema can fill the alveolar spaces with hyaline membrane formation, compatible with early-phase acute respiratory distress syndrome (ARDS).

Joost Wiersinga W. eta al. JAMA Review 2020 doi:10.1001/jama.2020.12839

The Road to COVID-19 EUA Approval

Tocilizumab

1/8/2010 FDA approval for treatment of moderate to severe rheumatoid arthritis

8/31/2017 FDA approval for treatment of CAR T cell-induced cytokine release syndrome

6/24/2021 EUA authorization for COVID-19 hospitalized adults and children

Baricitinib

6/1/2018 FDA approval for treatment of moderate to severe rheumatoid arthritis

11/19/2020 EUA for baricitinib in combination with remdesivir for COVID-19 hospitalized adults and children

Tocilizumab: Key COVID-19 Trials

Baricitinib: Key COVID-19 Trial

Tocilizumab For Treatment of COVD-19

Baricitinib For Treatment of COVD-19

Baricitinib Dose Adjustments Due to Laboratory Abnormalities

FDA Emergency Use Authorization for Baricitinib 11/19/2020

https://media.blubrry.com/pharmsohard/pdcn.co/e/http://feeds.soundcloud.com/stream/1104663961-pharmsohard-the-immune-system-needs-to-calm-down-pharmacologic-management-with-tocilizumab-and-baricitinib.mp3?_=1

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | RSS | http://pharmsohard.com/

Exit mobile version